ERS Genomics inks licensing agreement with Applied StemCell

By The Science Advisory Board staff writers

September 15, 2020 -- ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.

Financial terms of the deal were not disclosed. ERS Genomics was formed to provide broad access to CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, PhD.

Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents, and genetically modified cell lines and organisms, ERS Genomics said.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.